Pharmaceuticals & Healthcare in Pakistan

You need a Drug Manufacturing Licence (DML) from DRAP for your facility, granted only after the plant passes a Good Manufacturing Practice (GMP) inspection, plus a separate product registration for every individual drug (each strength and dosage form is registered separately). You must also employ qualified technical staff (production and QC pharmacists/chemists) by law. All of this is governed by the DRAP Act 2012 and the Drugs Act 1976, and selling an unregistered drug is a criminal offence.

The maximum retail price of registered drugs is set by the federal government through DRAP under a drug pricing policy, so you cannot freely price your products and price increases are regulated and often contested. This squeezes margins, intensifies generic price competition, and exposes manufacturers who import APIs to currency risk while selling at controlled rupee prices. Model price control and API/FX exposure before launching, and note that supplements and health products are not price-controlled.

Product registration is known for long timelines that can run a year or more depending on the product category and DRAP's backlog, and you cannot manufacture or sell the product until it is registered. Generics of already-registered molecules follow a better-trodden, more predictable path than new molecules. Build this lead time into your launch plan from the start — registration, not the factory, is usually the binding constraint on going to market.

Good Manufacturing Practice is DRAP's standard covering premises design and segregation, HVAC/clean-room classification, water systems, qualified staff, documented SOPs, QC laboratories, stability testing and batch records. It makes manufacturing capital-heavy because you can't compromise on plant design, equipment qualification or the QC lab, and sterile/injectable production is far more demanding than oral solids. Many SMEs start with simpler dosage forms or use contract/toll manufacturing with an existing licensed plant.

Yes — several healthcare businesses don't require a DML. Retail pharmacies and drug distribution need a provincial drug sale licence (under a qualified person) but far less capital. Nutraceuticals and health supplements fall under DRAP's lighter Alternative Medicines and Health Products regime. Medical devices, diagnostics, laboratories, and health-tech (telemedicine, clinic software, e-pharmacy) are other lower-barrier entries, each with their own rules but without full drug-manufacturing GMP requirements.

Health and food supplements/nutraceuticals are regulated under DRAP's Alternative Medicines and Health Products rules, which are generally lighter and faster than full drug registration and — importantly — are not price-controlled, so margins are freer. This makes the segment a popular lower-barrier entry. However, enforcement against unsubstantiated health and therapeutic claims is tightening, so brands must be careful about what they claim on labels and in marketing.

You need a drug sale licence from the provincial drug authority for the appropriate licence category, and the pharmacy must operate under a qualified person (pharmacist or the category-appropriate qualified individual). The premises must meet storage requirements (including refrigeration for temperature-sensitive stock) and is subject to inspection. Register the business with FBR for an NTN. Selling drugs without a valid sale licence, or stocking unregistered/spurious drugs, exposes you to seizure and prosecution.

You need the underlying DRAP manufacturing licence and product registration, plus export documents from DRAP — a Certificate of Pharmaceutical Product (CoPP) and Free Sale Certificate — and GMP certification, along with registration of the product in the destination country (usually driven by your local agent/distributor there). Standard export paperwork (certificate of origin, invoice, packing list) applies. Pakistani pharma mostly exports to less stringently regulated markets; reaching the EU/US requires their own inspections.

For many export markets, WHO-GMP certification is the entry requirement, and PIC/S-aligned compliance broadens your reach. For the EU you need EU-GMP (an EMA/member-state inspection) and for the US an FDA inspection. Pakistani exports skew toward Afghanistan, Africa and Central Asia precisely because most local firms haven't climbed to the higher GMP tiers. Investing in WHO-GMP/PIC/S is the strategic path out of the low-margin, low-regulation export segment into higher-value markets.

Sialkot is a globally significant manufacturing and export cluster for surgical and dental instruments, supplying many markets with cost-competitive instruments. The cluster's strategic challenge is moving up from low-cost commodity instruments to certified, higher-value branded devices. Reaching premium markets requires international certifications — ISO 13485 (medical device quality management), CE marking for Europe, and FDA registration for the US — and that certification climb is where SME differentiation and margin lie.

DRAP regulates medical devices under a risk-based classification (commonly Class A through D, from low to high risk), requiring an establishment licence for the manufacturer/importer and registration or enlistment of the device depending on its class. Higher-risk devices face stricter requirements. For export to premium markets, international standards like ISO 13485 and CE/FDA matter more than domestic registration. Confirm your device's class and the corresponding DRAP pathway before investing.

Most active pharmaceutical ingredients (APIs) used by Pakistani manufacturers are imported, largely from China and India, while finished-drug prices are controlled in rupees. When the rupee devalues, input costs rise but you can't freely raise the controlled price, squeezing margins and periodically causing shortages of unprofitable essential drugs. Any pharma SME must model API import cost and currency exposure, and consider sourcing strategy and inventory hedging, before committing to price-controlled molecules.

Yes. Under the Drugs Act 1976 and the DRAP Act 2012, manufacturing, importing or selling an unregistered, spurious, adulterated or misbranded drug is a punishable offence, not a mere paperwork lapse. DRAP and provincial drug inspectors can seize stock, seal premises and prosecute, and drug courts hear such cases. This is why product registration timelines must be respected and why every product in your supply chain needs valid registration.

Pharmacovigilance is the monitoring and reporting of adverse drug reactions and safety signals. DRAP requires manufacturers and importers to maintain pharmacovigilance systems to capture and report safety data. It is an ongoing legal and quality obligation, not optional, alongside batch traceability, recall capability and stability monitoring. Treat it as a permanent operating function with assigned responsibility, because failure to report safety issues carries regulatory and legal consequences.

E-pharmacy and online drug sale exist but sit in an evolving and sensitive regulatory area, because selling prescription drugs online raises authenticity, prescription-verification and licensing concerns that DRAP and provincial authorities watch closely. You still need the underlying drug sale licences and qualified-person oversight, and you must handle prescriptions and cold-chain items properly. Proceed carefully, monitor current DRAP guidance on online sale, and don't assume a website exempts you from physical-pharmacy licensing rules.

Contract/toll manufacturing lets you have your products made at an existing DRAP-licensed, GMP-compliant plant instead of building your own facility, dramatically lowering capital and compliance burden. You focus on product selection, registration (registrations are still required), branding and distribution while the contract manufacturer provides GMP capacity. It's a common route for SMEs entering generics or supplements, though you still bear regulatory responsibility for your registered products and their quality.

Register with FBR for an NTN and the appropriate sales-tax regime. Pharma products have nuanced treatment — some essential drugs have had exemptions or zero-rating, with policy changing over time — so SKU-level classification with a tax advisor is essential. Certain healthcare services may attract provincial sales tax on services (PRA, SRB, etc.) depending on activity and province. Confirm current rates and treatment rather than assuming, because pharma tax policy shifts with each budget.

Critical for temperature-sensitive products and absolutely mandatory for vaccines and biologicals. Good distribution and storage practices require an unbroken temperature-controlled chain, and DRAP and provincial inspectors check storage conditions. A single excursion can render product unsafe and unsaleable. Distributors and any SME handling such products need refrigerated storage, monitored/reefer transport, temperature logging, and backup power against load-shedding — treat these as core infrastructure, not optional add-ons.

A retail pharmacy or small distribution operation can start as a sole proprietor/AOP with an FBR NTN and the relevant drug sale licence. But manufacturing, importing, or any venture seeking investment, hospital/government tenders, or institutional credibility should be an SECP private limited company under the Companies Act 2017 — and manufacturers almost always are, given the capital and compliance involved. Incorporation also gives limited liability, which matters in a high-liability regulated sector.

Treating compliance as a one-time licensing hurdle rather than a continuous quality system, underestimating product-registration timelines and trying to launch before registration, ignoring API import/FX exposure on price-controlled molecules, attempting sterile/injectable manufacturing without the much higher GMP investment it needs, and neglecting cold chain for temperature-sensitive stock. Many also confuse the lighter supplement regime with full drug rules — or vice versa — and end up either over-investing or non-compliant.

Decide your tier: full drug manufacturing (capital- and DRAP-heavy), import/distribution, retail pharmacy, supplements/nutraceuticals, medical devices, or health-tech — each has a very different regulatory and capital profile. Then map the exact DRAP and/or provincial drug-authority approvals that tier requires and sequence them first, because they are the long pole and the legal precondition for trading. Register with FBR, choose your structure (SECP company for anything serious), and budget for ongoing compliance, not just setup.

The Certificate of Pharmaceutical Product (CoPP) and Free Sale Certificate are issued by DRAP and certify that your product is registered and freely sold in Pakistan and that your facility is GMP-compliant — importing countries require these to register your product in their market. You apply through DRAP with your manufacturing licence, product registration and GMP credentials in order. Your distributor/agent in the destination country then uses them to drive local registration there.